The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions

Clinical and Experimental Metastasis

Volumn 21, Issue 3, 2004, Pages 191-199

  Davidson, Ben ^a,b   Goldberg, Iris ^c   Tell, Liora ^c   Vigdorchik, Sophya ^d   Baekelandt, Mark ^a   Berner, Aasmund ^a   Kristensen, Gunnar B ^a   Reich, Reuven ^d   Kopolovic, Juri ^b,c  

^a UNIVERSITY OF OSLO   (Norway)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Ets transcription factors; metastasis; mRNA in situ hybridization; serous effusions

Indexed keywords

INTEGRIN; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PEA3; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER LOCALIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; EFFUSION; FEMALE; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; METASTASIS; OVARY CARCINOMA; PREDICTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOLID TUMOR; STATISTICAL SIGNIFICANCE; SURVIVAL; TUMOR GROWTH; UPREGULATION;

BASE SEQUENCE; DNA PRIMERS; DNA-BINDING PROTEINS; FEMALE; HUMANS; IN SITU HYBRIDIZATION; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEIN C-ETS-2; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 4344600296     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CLIN.0000037703.37275.35     Document Type: Article

References (54)

1. Jemal H, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. Verger A, Duterque-Coquillaud M. When Ets transcription factors meet their partners. BioEssays 2002; 24: 362-70.
3. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001; 2: 827-37.
4. Davidson B, Reich R, Goldberg I et al. Ets-1 mRNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res 2001; 7: 551-7.
5. Borden P, Heller RU. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukar Gene Exp 1997; 7: 159-78.
6. Lengyel E, Stepp E, Gum R, Boyd D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem 1995; 270: 23007-12.
7. Oda N, Abe M, Sato Y. Ets-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin β-3. J Cell Physiol 1999; 178: 121-32.
8. Xin JH, Cowie A, Lachance P, Hassel JA. Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells. Genes Dev 1992; 6: 481-96.
9. Monte D, Coutte L, Baert JL et al. Molecular characterization of the Ets-related human transcription factor ER81. Oncogene 1995; 11: 771-9.
10. Monte D, Baert JL, Defossez PA et al. Molecular cloning and characterization of human ERM, a new member of the Ets family closely related to mouse PEA3 and ER81 transcription factors. Oncogene 1994; 9: 1397-406.
11. Higashino F, Yoshida K, Fujinaga Y et al. Isolation of a new cDNA encoding the adenovirus E1A enhancer binding protein: A new human member of the ets oncogene family. Nucleic Acid Res 1993; 21: 547-53.
12. Yoshida K, Narita M, Fujinaga Y. Binding sites of HeLa cell nuclear proteins on the upstream region of adenovirus type 5 E1A gene. Nucleic Acids Res 1989; 17: 10015-34.
13. Higashino F, Yoshida K, Noumi T et al. Ets-related protein E1A-F can activate three different matrix metalloproteinase gene promoters. Oncogene 1995; 10: 1461-3.
14. Trimble MS, Xin JH, Guy CT et al. PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas. Oncogene 1993; 8: 3037-42.
15. Shepherd TG, Kockeritz L, Szrajber MR et al. The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr Biol 2001; 11: 1739-48.
16. Benz CC, O'Hagan RC, Richter B et al. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 1997; 15: 1513-25.
17. Kinoshita J, Kitamura K, Tanaka S et al. Clinical significance of PEA3 in human breast cancer. Surgery 2002; 131: S222-5.
18. Xing X, Wang SC, Xia W et al. The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 2000; 6: 189-95.
19. Guerra-Vladusic FK, Vladusic EA, Tsai MS, Lupu R. Signaling molecules implicated in heregulin induction of growth arrest and apoptosis. Oncol Rep 2001; 8: 1203-14.
20. Baert JL, Monte D, Musgrove EA et al. Expression of the PEA3 group of Ets-related transcription factors in human breast-cancer cells. Int J Cancer 1997; 70: 590-7.
21. Hiroumi H, Dosaka-Akita H, Yoshida K et al. Expression of E1AF/PEA3, an Ets-related transcription factor in human non-small-cell lung cancers: Its relevance in cell motility and invasion. Int J Cancer 2001; 93: 786-91.
22. Hida K, Shindoh M, Yasuda M et al. Antisense E1AF transfection restrains oral cancer invasion by reducing matrix metalloproteinase activities. Am J Pathol 1997; 150: 2125-32.
23. Hida K, Shindoh M, Yoshida K et al. Expression of E1AF, an ets-family transcription factor, is correlated with the invasive phenotype of oral squamous cell carcinoma. Oral Oncol 1997; 33: 426-30.
24. Gavrilov D, Kenzior O, Evans M et al. Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. Eur J Cancer 2001; 37: 1033-40.
25. Simpson S, Woodworth CD, DiPaolo JA. Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines. Oncogene 1997; 14: 2149-57.
26. Nishikawa A, Iwasaki M, Akutagawa N et al. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: Correlation to invasive potential. Gynecol Oncol 2000; 79: 256-63.
27. Ito Y, Miyoshi E, Takeda T et al. Linkage of elevated Ets-2 expression to hepatocarcinogenesis. Anticancer Res 2002; 22: 2385-90.
28. Ito Y, Takeda T, Okada M, Matsuura N. Expression of Ets-1 and Ets-2 in colonic neoplasms. Anticancer Res 2002; 22: 1581-4.
29. Reddy ESP, Rao VN, Papas TS. The erg gene: A human gene related to the ets oncogene. Proc Natl Acad Sci USA 1987; 84: 6131-5.
30. Sorensen PHB, Lessnick SL, Lopez-Terrada D et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6: 146-51.
31. Yi HK, Fujimura Y, Ouchida M et al. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Oncogene 1997; 14: 1259-68.
32. Buttice G, Duterque-Coquillaud M, Basuyaux JP et al. Erg, and Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene 1996; 13: 2297-306.
33. Davidson B, Risberg B, Goldberg I et al. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol 2001; 25: 1493-500.
34. Davidson B, Goldberg I, Gotlieb WH et al. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin Cancer Res 2003; 9: 1412-9.
35. Davidson B, Risberg B, Kristensen G et al. Detection of cancer cells in effusions from patients diagnosed with gynecological malignancies - evaluation of five epithelial markers. Virchows Arch 1999; 435: 43-9.
36. Davidson B, Berner A, Nesland JM et al. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma - evidence of up-regulated Tn and Sialyl Tn antigens expression in effusions. Hum Pathol 2000; 31: 1081-7.
37. Davidson B, Bemer A, Nesland JM et al. E-cadherin and α-, β- and γ-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol 2000; 192: 460-9.
38. Reed JA, Manahan LJ, Parks CS, Brigati DJ. Complete one-hour immunocytochemistry based on capillary action. Biotechniques 1992; 13: 434-43.
39. Davidson B, Goldberg I, Gotlieb WH et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metast 1999; 17: 799-808.
40. Davidson B, Reich R, Berner A et al. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer 2001; 37: 2040-9.
41. Davidson B, Goldberg I, Berner A et al. Expression of membrane-type 1,2 and 3 matrix metalloproteinases (MT1-MMP, MT2-MMP, MT3-MMP) mRNA in ovarian carcinoma cells in serous effusions. Am J Clin Pathol 2001; 115: 517-24.
42. Davidson B, Reich R, Kopolovic J et al. Interleukin-8 and vascular endothelial growth factor mRNA levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin Exp Metast 2002; 19: 135-44.
43. Davidson B, Goldberg I, Berner A et al. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metast 2003; 20: 161-9.
44. Davidson B, Goldberg I, Reich R et al. The αv and β1 integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 2003; 90: 248-57.
45. Givant Horwitz V, Davidson B, van de Putte G et al. Dissociated mRNA expression of the 67 kDa laminin receptor and the α6 integrin subunit in serous ovarian carcinoma. Clin Exp Metast 2003; 20: 599-609.
46. Davidson B, Risberg R, Reich R, Berner A. Effusion cytology in ovarian cancer - new molecular methods as aids to diagnosis and prognosis. Clin Lab Med 2003; 23: 729-54.
47. Davidson B, Goldberg I, Kopolovic J et al. Expression of angiogenesis-related genes in ovarian carcinoma - a clinicopathologic study. Clin Exp Metastas 2000; 18: 501-7.
48. Goldberg I, Davidson B, Reich R et al. αV integrin is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clin Cancer Res 2001; 7: 4073-9.
49. Besser D, Presta M, Nagamine Y. Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. Cell Growth Differ 1995; 6: 1009-17.
50. Hapke S, Gawaz M, Dehne K et al. beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol Cell Biol 2001; 21: 2118-32.
51. Tremble P, Damsky CH, Werb Z. Components of the nuclear signaling cascade that regulate collagenase gene expression in response to integrin-derived signals. J Biol Cell 1995; 129: 1707-20.
52. Iguchi A, Kitajima I, Yamakuchi M et al. PEA3 and AP1 are required for constitutive IL-8 gene expression in hepatoma cells. Biochem Biophys Res Commun 2000; 279: 166-71.
53. Dieterich M, Goodman SN, Rojas-Corona RR et al. Multivariate analysis of prognostic features in malignant pleural effusions from breast cancer patients. Acta Cytol 1994; 38: 945-52.
54. Banerjee AK, Willetts I, Robertson JF, Blamey RW. Pleural effusion in breast cancer: A review of the Nottingham experience. Eur J Surg Oncol 1994; 20: 33-6.